Vicodin vex: DEA tightens restrictions on hydrocodone combos

From NeurologyWire

On Friday the US Drug Enforcement Administration (DEA) will move hydrocodone combination products (HCPs) from Schedule III to the more-restrictive Schedule II.Pure hydrocodone drugs have been listed as Schedule II drugs since the creation of the list in 1971. But hydrocodone-combination products (HCPs)those made with specified amounts of other ther...

Login to read story

Thursday, September 04, 2014

Show last days of articles

National Survey Seeks To Shed Light On Impact Of Rare Seizur...

From NeurologyWire

A new landmark U.S. seizure disorder survey is being commissioned by the Epilepsy Foundation (EF) to shed light on the burden of illness associated wi...Full story

Wednesday, September 03, 2014

Child-parent bedsharing impairs sleep quality in study

From NeurologyWire

Bedsharing reduce infants sleep duration and leads to a higher number of awakenings, suggests a new study in Journal of Developmental and Behavioral P...Full story

NICO BrainPath Medical Device for Safely Accessing the Brain...

From NeurologyWire

Indianapolis medical device maker NICO Corporation was recognized with the Indiana Innovation Award for its BrainPath technology used for safely and a...Full story

Tuesday, September 02, 2014

Nuplazid (pimavanserin) receives breakthrough therapy design...

From NeurologyWire

Acadia Pharmaceuticals Inc. said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Nuplazid (pimavanserin) f...Full story

Vimpat approved by FDA as monotherapy for partial-onset seiz...

From NeurologyWire

UCB announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Vimpat (lacosamide) C-V as ...Full story

EMD Serono Appoints Drew Young to Senior Vice President, Neu...

From NeurologyWire

From the press release:EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Drew Young has joined the company as Sen...Full story

Thursday, August 28, 2014

Civitas raises $55M for Phase III Parkinson's study, doesn't...

From NeurologyWire

Civitas Therapeutics announced they have raised $55 million through Series C financing, to be used toward the upcoming Phase III clinical trials for t...Full story

Wednesday, August 27, 2014

Lack of key protein linked to dementia

From NeurologyWire

Scientists at the University of Warwick have provided the first evidence that the lack of a naturally occurring protein is linked to early signs of de...Full story

Tuesday, August 26, 2014

Wii Balance Board induces changes in MS patients

From NeurologyWire

A balance board accessory for a popular video game console can help people with multiple sclerosis (MS) reduce their risk of accidental falls, accordi...Full story

FDA reiterates that, no, dietary supplements cannot treat a ...

From NeurologyWire

When it's back-to-school time, it's also back to football, soccer and other sports that may cause a head injury. That makes it prime time to exploit t...Full story

Friday, August 22, 2014

HHS sets Oct. 1 deadline for transition to ICD-10

From NeurologyWire

The U.S. Department of Health and Human Services (HHS) set Oct. 1, 2015 as the new compliance date for health care providers, health plans, and health...Full story

Thursday, August 21, 2014

Rob Schneider's PD Twitter Rant Off Base

From NeurologyWire

Comedian Rob Schneider went on a Twitter rant blaming Parkinson's drugs for Robin Williams' death, and he isn't backtracking. Williams' widow said he ...Full story

Wednesday, August 20, 2014

Drug used for dementia symptoms carries kidney risks

From NeurologyWire

Atypical antipsychotic drug use is associated with an increased risk for acute kidney injury (AKI), according to a new study in the Annals of Internal...Full story

Cholesterol drug cuts heart and stroke risks by 30 percent i...

From NeurologyWire

The cholesterol-lowering drug fenofibrate cuts cardiovascular disease risks by 30 per cent in women with type-2 diabetes, a new University of Sydney s...Full story

Monday, August 18, 2014

Epilepsy drug Fycompa rebuffed, again, in Germany

From NeurologyWire

The German Institute for Quality and Efficiency in Healthcare (IQWiG) has said that epilepsy drug Fycompa (perampanel) from Japanese drug major Eisai ...Full story